Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

GI and liver > nausea and vomiting > Flashcards

nausea and vomiting Flashcards

1
Q

other Sxs associated with NV?

A

palor, diaphoresis, tachycardia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

causes of NV

A

GI disorders (flu, pathogen, ulcer, GERD, pancreatitis, cholecystitis, obstruction, tumor, DM gastroparesis), CNS disorders (anxiety, tumor, HA), pain (acute* or chronic), excessive intake of anything (food or alcohol), cyclic vomiting syndrome (bouts of severe NV that can last for days, no known cause, associated with migraine HA, may be triggered by stress, children more often than adults), pregnancy (80%, begins week 4-7, resolves week 20, hyperemesis gravidarum (under 1%))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

treatment-induced causes of NV

A 
anti-neoplastic agents
radiation
opioids
anesthesia
procedures (especially abdominal)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

complications of NV

A

discomfort, dehydration (K+, Na+, Cl-), malnutrition, aspiration pneumonia, anxiety, compromise therapy, decreased QOL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

assessment of NV

A

number of episodes, onset, duration of Sxs, severity (1-10)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

questions to ask patients presenting with NV

A

how long have you had NV?
what color is your vomitus?
how often do you vomit?
is vomiting related to eating? if so, what food and how soon after?
do you have nausea without vomiting?
is the NV associated with … ? (signs of other problems)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

site of action of drugs that treat NV

A 
dopamine receptors (D2)
histamine receptors (H1 and H2)
muscarinic receptors - cholinergic receptors (M)
serotonin receptors (5-HT3)
neurokinin receptors (NK-1)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

non-pcol management of NV

A

determine cause
put the gut to rest - clear liquid diet and IV hydration
dietary - avoid favorite foods, avoid fatty, fried, sweet and spicy foods, eat food cold or at room temp
physical - avoid unpleasant sights, sounds and odors that may aggravate, get fresh air, avoid sudden movements, dim lights, acupressure, nerve stimulation therapy (relief band? - returns stomach to a normal rhythm)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

treatment of nausea secondary to dyspepsia

A 
antacids (maalox, mylanta, tums, peptobismol)
H2 antagonists (zantac, pepcid)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

antihistamines-anticholinergics to treat NV

A

limited for mod-severe NV
MOA: block histamine and/or muscarinic receptors in the CTZ and NTS centers
SE: drowsiness**, sedation, dry mouth, constipation, blurred vision

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

phenothiazines

A

prochlorperazine, promethazine
MOA: dopamine inhibition at CTZ
SE: dizziness, sedation, dry mouth, hypotension, EPS (children, young adults, elderly)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

serotonin antagonists

A

ondansetron, granisetron, palonosetron
MOA: serotonin inhibition at CTZ, NTS, and GI tract
very effective
SE: mild HA, constipation, dizziness, QT prolongation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

advantages/disadvantages of various serotonin antagonists

A

ondansetron: multiple dosage forms (inc. ODT), generic, low cost
granisteron: multiple dosage forms (patch, inj, SC), generic, low cost
palonosetron: long DOA, brand only, no PO dosage form
NO SUPPOSITORY FOR ANY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

granisetron dosage forms

A

sancuso
patch: apply 24-48 hours before chemo, may be worn up to 7 days, avoid sun exposure to site and for up to 10 days, $$$
sustol
ER injection: acute delayed CINV, polymer-based drug delivery technology, efficacy greater than 5 days, 10 mg SC no more often than q 7 days, administer over 20-30 seconds d/t viscosity, not recommended for use longer than 6 months

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

butyrophenones

A

MOA: dopamine inhibition at CTZ
SE: sedation, hypotensoin, EPS*
black box warning: risk of EKG abnormalities (need 12-lead EKG + 2-3 hour post-op monitoring)
droperidol
haloperidol (1-5 mg IM/IV/PO q 1-5 hours)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

olanzapine

A

MOA: blocks D2, 5-HT2c and 5-HT3 receptors - excellent for breakthrough NV, no IV formula
side effects: sedation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

NK-1 antagonists

A

MOA: neurokinin receptor inhibition at CTZ, NTS and GI tract
SE: fatigue, dizziness, HA
aprepitant: for both acute and delayed CINV, not monotherapy, 125 mg day 1, 80 mg day 2 & 3, drug interactions (must decrease dexamethasone by 50%), expensive
fosaprepiant: for acute CINV, not monotherapy, 150 mg IV day 1, expensive
rolapitant: indicated for delayed CINV, not monotherapy, 180 mg as a single dose 1-2 hours before chemo, SE: neutropenia, hiccups, dec appetite, $$$
netupitant and palonosetron: indicated for both acute and delayed CINV, 300/0.5 mg PO 1-2 hours prior to chemo (covers days 1,2,3), used with dexamethasone, SE: headache, asthenia, dyspepsia, fatigue, constipation, $$$

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

cannabinoid use in NV

A

dronabinol and nabilone
MOA: binds with cannabinoid or CB1 receptors in the brain
efficacy similar to phenothiazines and metoclopramide
indications: unresponsive NV, wasting in patients with chronic disease, stimulate appetite, some pain management, MS
SE: sedation, dry mouth, euphoria, dysphoria

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

corticosteroid use in NV

A

MOA: inhibition of cortical input into vomiting center?
SE: insomnia, agitation, mild euphoria
low risk of ADRs
dexamethasone

20
Q

benzo use in NV

A

lorazepam, alprazolam
MOA: inhibition of cortical input into vomiting center
especially useful for anticipating NV - start PO day prior to chemo and IV just prior to chemo
SE: sedation, amnesia

21
Q

benzamide use in NV

A

metoclopramide
MOA: dopamine inhibition at CTZ, serotonin inhibition at CTZ, NTS, & GI tract
dose: 20-50 mg
SE: drowsiness, sedation, diarrhea; restlessness, agitation, EPS (use benadryl to prevent EPS)

22
Q

treating NV associated with severe pain

A

5HT3 antagonists

23
Q

scopolamine

A

apply 6-8 hours before needed

duration = 72 hours

24
Q

dimenhydrinate

A

dramamine

50 mg PO taken 30-60 min before needed

25
Q

meclizine

A

25 mg PO taken 30-60 min before needed

26
Q

treating NV during pregnancy

A 
dietary modifications
herbal therapy
-ginger root (1 gram in divided doses, efficacy similar to B6, onset is 3 days)
-ginger gum
-peppermint oil
-best for mild cases
B6 25 mg TID + doxylamine 12.5 TID
metoclopramide 5-10 mg TID
ondansetron 4-8 mg up to TID
meclizine
dimenhydrinate
promethazine
prochloperazine
27
Q

hyperemesis gravidarum treatment

A

metoclopramide and ondansetron SQ infusions

similar to using an insulin pump

28
Q

post-op NV

A

very common w older inhaled anesthetic agents
patients with multiple risk factors are at highest risk for PONV
most common complication associated with ambulatory surgery
prevention is more effective than treatment

29
Q

risk factors for PONV

A

female
non-smoker
Hx of PONV or motion sickness
anesthetic: intra-operative use of volatile anesthetics (less w propofil), use of NO
surgical: duration of surgery, type of surgery (laprascopic, craniotomy, ENT)

30
Q

treatment of PONV

A

low risk: 0-1 factors, no prophylaxis, treat PRN
mod-high: 2+ risk factors, prophylaxis with 1-2 antiemetics (1 if using propofol), 5HT3 is DOC, all classes can be used
highest risk: always use 2 agents (5HT3 antagonist + metoclopramide or aprepitant)
breakthrough: use an agent from a different class if within 6 hours

31
Q

aprepitant in PONV

A

40 mg 1-3 hours prior to induction of anesthesia

32
Q

acute emesis CINV

A

begins within 1-2 hours after administration, symptoms reach maximum intensity after 5-6 hours and resolve within 12-24 hours

33
Q

delayed emesis CINV

A

most difficult to treat
follows acute emesis (post 24 hours) - less severe but more bothersome
peak onset 48-72 hours after chemotherapy administration
gradually diminishes over next 1-3 days
may persist up to 1 week after chemotherapy treatment; - may worsen with repeated courses
more common with high-doses of certain agents, especially cisplatin
no clear MOA, but appears to differ somewhat from acute emesis

34
Q

anticipatory emesis CINV

A

conditioned response to a conditioned stimuli
usually develops after 4-5 cycles of cehmo
more common in patients with history of severe uncontrolled emesis
generally occurs before treatment begins

35
Q

factors affecting CINV

A

female
age (decreased likelihood as age increases)
EtOH intake (less chance in Hx of chronic intake)
prior chemo (increases chance if emesis poorly controlled)
predisposition to NV (motion sickness)
personality (anxious)
emetogenic potential of chemo (cisplatin, cyclophospamide + doxorubin)
dose and dosage regimen (large doses, later in cycles, less with fractionated regimen)
combination therapy

36
Q

preventing acute CINV

A

assess the individual situation
assess the emetogenic potential of the agents and regimen
always treat when risk is mod-high
use PO therapy whenever possible

37
Q

regimen for prevention of acute CINV in high emetic risk patients

A 
5HT3 antagonist 
-ondansetron 16 mg PO or 8-16 mg IV
-granisetron 2 mg PO or 1 mg IV
-palonosetron 0.25 mg IV
dexamethasone
-12 mg IV/PO day 1, then 8 mg daily days 2-4
aprepitant 
-125 mg PO day 1 then 80 mg days 2-3
\+/- lorazepam
0.5-2 mg IV or PO q46h PRN days 1-4

netupitant: 300 mg PO on day 1
palonosetron: 0.5 mg PO on day 1
dexamethasone: 20 mg PO on day 1, then 8 mg BID on days 2-4
+/- lorazepam: 0.5-2 mg IV or PO q46h PRN days 1-4

olanzapine: 10 mg PO on days 1-4
dexamethasone: 20 mg IV on day 1, then 8 mg BID on days 2-4
palonosetron: 0,25 mg IV on day 1
+/- lorazepam: 0.5-2 mg IV or PO q46h PRN days 1-4

38
Q

prevention of acute CINV in moderate emetic risk patients

A 
5HT3 antagonist (palonosetron is preffered)
dexamethasone: days 1-3
39
Q

prevention of acute CINV in low emetic risk patients

A 
any of the following:
dexamethasone* 12 mg po/IV daily
metoclopramide 10-40 mg PO/IV, then q6h
prochlorperzine 10 mg PO/IV, then q6h
ondansetron 16 mg PO daily
granisetron 2 mg PO daily

minimal emetic risk: use agents PRN

40
Q

breakthrough NV during chemo

A

difficult to control
give agent from a different* drug class
IV or PR administration often required
ATC rather than PRN dosing

41
Q

treatment of breakthrough NV during chemo

A 
prochloperazine - 10 mg IV q46h PRN
nabilone - 1-2 g PO q12h
metoclopramide - 10-40 mg IV q46h prn + benadryl 50 mg IV
haloperidol - 0.5-2 mg q46h PRN
olanzapine - 10 mg PO daily
42
Q

delayed NV overview

A

risk for acute CINV = risk for delayed CINV
complete control may only be 50%
clinicians often over-estimate efficacy of typical PRN regimens for delayed CINV

43
Q

treatment and prevention of delayed NV

A

metoclopramide + dexamethasone
ondansetron or granisetron + dexamethasone
palonosetron +/- dexamethasone
olanzapine + 5HT3
aprepitant
add something the patient hasn’t had
carries over from acute treatment….
aprepitant 125 mg 1 hour prior to chemo and then 80 mg on days 2 and 3
plus dexamethsone 4-8 mg x 3-5 days starting on day 2

44
Q

unresponsive delayed NV

A

nabilone, dronabinol, medical marijuana

better in young patients

45
Q

monitoring antiemetic therapy efficacy

A 
volume of vomit
frequency and duration of vomiting
nausea 0-10
ability to maintain food/liquid
# of PRN doses of antiemetics
QOL rating
46
Q

monitoring antiemetic therapy toxicity

A 
sedation/drowsiness
dizziness
diarrhea
headache
anticholinergic SE
EPS

GI and liver (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions